Plasma Biomarkers and Disease Prognosis in Mild Cognitive Impairment with Lewy Bodies

IF 7.4 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders Pub Date : 2025-03-29 DOI:10.1002/mds.30181

Paul C. Donaghy PhD, Jahfer Hasoon MB, BS, Calum A. Hamilton PhD, Joanna Ciafone PhD, Rory Durcan PhD, Nicola Barnett MSc, Kirsty Olsen MRes, Sarah Lawley MB, BS, Gemma Greenfinch PhD, Michael Firbank PhD, Amanda Heslegrave PhD, Henrik Zetterberg MD, PhD, Louise Allan PhD, John T. O'Brien DM, John-Paul Taylor PhD, Alan J. Thomas PhD

{"title":"Plasma Biomarkers and Disease Prognosis in Mild Cognitive Impairment with Lewy Bodies","authors":"Paul C. Donaghy PhD, Jahfer Hasoon MB, BS, Calum A. Hamilton PhD, Joanna Ciafone PhD, Rory Durcan PhD, Nicola Barnett MSc, Kirsty Olsen MRes, Sarah Lawley MB, BS, Gemma Greenfinch PhD, Michael Firbank PhD, Amanda Heslegrave PhD, Henrik Zetterberg MD, PhD, Louise Allan PhD, John T. O'Brien DM, John-Paul Taylor PhD, Alan J. Thomas PhD","doi":"10.1002/mds.30181","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Little is known about the prognostic value of plasma biomarkers in mild cognitive impairment with Lewy bodies (MCI-LB).</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To investigate the association of four plasma biomarkers with disease progression in MCI.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Plasma amyloid-beta (Aβ)<sub>42/40</sub>, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and phosphorylated tau 181 (pTau181) were measured at baseline in a longitudinal MCI cohort (n = 131).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Baseline plasma NfL was associated with increased risk of dementia/death in the entire cohort. In MCI-LB, baseline plasma NfL, GFAP, and pTau181 were associated with increased risk of dementia/death and increased cognitive decline measured by the Addenbrooke's Cognitive Examination-Revised.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>pTau181, GFAP, and NfL are associated with more rapid disease progression in MCI-LB and, with further validation, could be useful to support prognosis and stratification for clinical practice and treatment trials. Further work, including clinicopathological studies, is needed to understand the biological correlates of these markers in MCI-LB. © 2025 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>\n </section>\n </div>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"40 6","pages":"1200-1205"},"PeriodicalIF":7.4000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.30181","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mds.30181","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Little is known about the prognostic value of plasma biomarkers in mild cognitive impairment with Lewy bodies (MCI-LB).

Objectives

To investigate the association of four plasma biomarkers with disease progression in MCI.

Methods

Plasma amyloid-beta (Aβ)_42/40, glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and phosphorylated tau 181 (pTau181) were measured at baseline in a longitudinal MCI cohort (n = 131).

Results

Baseline plasma NfL was associated with increased risk of dementia/death in the entire cohort. In MCI-LB, baseline plasma NfL, GFAP, and pTau181 were associated with increased risk of dementia/death and increased cognitive decline measured by the Addenbrooke's Cognitive Examination-Revised.

Conclusions

pTau181, GFAP, and NfL are associated with more rapid disease progression in MCI-LB and, with further validation, could be useful to support prognosis and stratification for clinical practice and treatment trials. Further work, including clinicopathological studies, is needed to understand the biological correlates of these markers in MCI-LB. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

查看原文本刊更多论文

路易体轻度认知障碍患者血浆生物标志物与疾病预后

背景血浆生物标志物在轻度认知障碍伴路易体（MCI - LB）中的预后价值尚不清楚。目的探讨四种血浆生物标志物与MCI疾病进展的关系。方法在纵向MCI队列（n = 131）中测定血浆淀粉样蛋白（a β）42/40、胶质纤维酸性蛋白（GFAP）、神经丝光（NfL）和磷酸化tau 181 （pTau181）的基线值。结果在整个队列中，基线血浆NfL与痴呆/死亡风险增加相关。在MCI - LB中，基线血浆NfL、GFAP和pTau181与痴呆/死亡风险增加和Addenbrooke's cognitive Examination - Revised测量的认知能力下降增加相关。结论：sptau181、GFAP和NfL与MCI - LB更快的疾病进展相关，经进一步验证，可用于支持临床实践和治疗试验的预后和分层。进一步的工作，包括临床病理研究，需要了解这些标志物在MCI‐LB中的生物学相关性。©2025作者。Wiley期刊有限责任公司代表国际帕金森和运动障碍学会出版的《运动障碍》。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Movement Disorders 医学-临床神经学

CiteScore

13.30

自引率

8.10%

发文量

371

审稿时长

12 months

期刊介绍： Movement Disorders publishes a variety of content types including Reviews, Viewpoints, Full Length Articles, Historical Reports, Brief Reports, and Letters. The journal considers original manuscripts on topics related to the diagnosis, therapeutics, pharmacology, biochemistry, physiology, etiology, genetics, and epidemiology of movement disorders. Appropriate topics include Parkinsonism, Chorea, Tremors, Dystonia, Myoclonus, Tics, Tardive Dyskinesia, Spasticity, and Ataxia.